SGLT2 inhibitor associated diabetic ketoacidosis
نویسندگان
چکیده
منابع مشابه
Euglycemic Diabetic Ketoacidosis in a Patient with Type II Diabetes Mellitus, Ascites and Poor Nutrition on SGLT2 Inhibitor
Title: This is the case of a patient with Euglycemic Diabetic Ketoacidosis (euDKA), ascites, poor nutrition and diabetes mellitus type II on SGLT2 inhibitor. Background: euDKA is an under-reported and under-diagnosed condition that mainly occurs in type I diabetes mellitus patients and in patients with prolonged starvation. The aim of this report is to shed the light on an additional risk facto...
متن کاملSodium-Glucose Transporter Type 2 (SGLT2) Inhibitor for Diabetic Kidney
In diabetes, both activation of renin-angiotensin system and glomerular hyperfiltration are seen even before the development of diabetic nephropathy. Glomerular hyperfiltration depends on glomerular hypertension sue to pathophysiological afferent arteriolar dilation. Tubular hypothesis has been proposed more than a decade ago to explain the above in type1 diabetes. Recently, clinical evidences ...
متن کاملAntipsychotic medicines associated with diabetic ketoacidosis
All patients should be screened for hepatitis B before starting treatment with direct-acting antivirals for hepatitis C. Patients co-infected with hepatitis B and C who are treated with directacting antivirals should be monitored and treated according to current clinical guidelines. The recommendations from the EMA are available here: Direct-acting antivirals for hepatitis C: EMA confirms r...
متن کاملDiabetic ketoacidosis associated with cocaine use.
BACKGROUND Multiple risk factors for diabetic ketoacidosis (DKA) have been described, including omission of insulin therapy and clinical conditions known to increase counterregulatory hormones. Recently, substance abuse has been identified in patients with DKA. We observed many cases of DKA in cocaine users, although the association between cocaine use and DKA has not been well described in the...
متن کاملOBSERVATIONS Diabetic Ketoacidosis Associated With Orlistat Treatment
O rlistat is a drug frequently prescribed as an adjuvant in weight control therapy (1–2). Orlistat inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to decrease the systemic absorption of dietary fat (1,2). In clinical trials, steatorrhoea and other gastrointestinal disorders are the most frequently reported side effects (3). Other reported adverse effects inclu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Case Reports and Images
سال: 2017
ISSN: 0976-3198
DOI: 10.5348/ijcri-201740-cr-10779